Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (581-590 of 869) with videos related to

Pageof 87
Sort By:
Oncogene|August 29, 2024
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Journal of Biomedical Optics|February 2, 2011
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapyJudith M Runnels, Alicia L Carlson, Costas Pitsillides, et al.
Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.
Pageof 87

Showing results (581-590 of 869) with videos related to

Sort By:
Pageof 87
Oncogene|August 29, 2024
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Journal of Biomedical Optics|February 2, 2011
Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapyJudith M Runnels, Alicia L Carlson, Costas Pitsillides, et al.
Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.
Pageof 87